Literature DB >> 29440112

SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications.

Emily J Meyer1,2,3, Genevieve Gabb2,4, David Jesudason5,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29440112     DOI： 10.2337/dc17-1721

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  27 in total

Review 1.  Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering.

Authors:  Brendon L Neuen; David Z Cherney; Meg J Jardine; Vlado Perkovic
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

2.  The Clinical Case for the Integration of a Ketone Sensor as Part of a Closed Loop Insulin Pump System.

Authors:  Melissa H Lee; Barbora Paldus; Balasubramanium Krishnamurthy; Sybil A McAuley; Rajiv Shah; Alicia J Jenkins; David N O'Neal
Journal:  J Diabetes Sci Technol       Date:  2019-01-10

3.  Empagliflozin as an adjunctive therapy for type 1 diabetes.

Authors:  Richard J MacIsaac; Melissa H Lee; Sybil A McAuley; Glenn M Ward; David N O'Neal
Journal:  Ann Transl Med       Date:  2018-12

4.  Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review.

Authors:  Ahmad Yehya; Archana Sadhu
Journal:  Clin Diabetes       Date:  2020-01

Review 5.  Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.

Authors:  Prasad Katulanda; Harsha A Dissanayake; Ishara Ranathunga; Vithiya Ratnasamy; Piyumi S A Wijewickrama; Nilukshana Yogendranathan; Kavinga K K Gamage; Nipun L de Silva; Manilka Sumanatilleke; Noel P Somasundaram; David R Matthews
Journal:  Diabetologia       Date:  2020-05-14       Impact factor: 10.122

Review 6.  Management of Diabetes in Patients Undergoing Bariatric Surgery.

Authors:  Christopher M Mulla; Harris M Baloch; Samar Hafida
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

7.  EUGLYCEMIC DIABETIC KETOACIDOSIS (EDKA) IN A PATIENT RECEIVING DAPAGLIFLOZIN.

Authors:  S M Sethi; M Vohra; S A Ali
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

Review 8.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield
Journal:  Eur J Clin Pharmacol       Date:  2019-08-03       Impact factor: 2.953

9.  Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.

Authors:  Labrini Papanastasiou; Spyridoula Glycofridi; Christos Gravvanis; Nikitas Skarakis; Irene Papadimitriou; Georgia Kanti; Chara Kapsali; Theodora Kounadi
Journal:  Hormones (Athens)       Date:  2020-11-05       Impact factor: 2.885

10.  Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.

Authors:  Michael Fralick; Donald A Redelmeier; Elisabetta Patorno; Jessica M Franklin; Fahad Razak; Tara Gomes; Sebastian Schneeweiss
Journal:  J Gen Intern Med       Date:  2021-02-09       Impact factor: 6.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.